Who Paid My Doc
Fariborz Delbakhsh
Summerfield, FL Medical Doctor
NPI 1548299712 CMS profile 115806
10770 Se 173Rd St, Summerfield, FL 34491
General payments
$5,353
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Fariborz Delbakhsh of Summerfield, FL is reported in the CMS Open Payments database as having received $5,353 across 214 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $910 | 41 | |
| 2024 | General | $890 | 35 | |
| 2023 | General | $966 | 39 | |
| 2022 | General | $827 | 29 | |
| 2021 | General | $836 | 30 | |
| 2020 | General | $362 | 22 | |
| 2019 | General | $561 | 18 |
Beside peers
- Fariborz Delbakhsh
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Fariborz Delbakhsh were reported at $910. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Fariborz Delbakhsh | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $561 | $197 | $63–$719 | $163 |
| 2020 | $362 | $126 | $38–$436 | $114 |
| 2021 | $836 | $151 | $45–$537 | $132 |
| 2022 | $827 | $175 | $53–$607 | $149 |
| 2023 | $966 | $183 | $57–$637 | $160 |
| 2024 | $890 | $185 | $56–$647 | $164 |
| 2025 | $910 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 185 drugsPart D claims
15,476
Drug cost
$1,605,896
Branded share of claims
18%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 238 | $346,304 | |
| Eliquis Apixaban | Brand | 129 | $188,428 | |
| Mounjaro Tirzepatide | Brand | 140 | $187,926 | |
| Januvia Sitagliptin Phosphate | Brand | 115 | $160,960 | |
| Farxiga Dapagliflozin Propanediol | Brand | 57 | $77,069 | |
| Rybelsus Semaglutide | Brand | 27 | $63,387 | |
| Jardiance Empagliflozin | Brand | 35 | $58,749 | |
| Xarelto Rivaroxaban | Brand | 48 | $58,270 | |
| Repatha Sureclick Evolocumab | Brand | 36 | $44,452 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 37 | $36,448 |
The 10 drugs with the highest cost, of 185 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 144 billing codesPaid by Medicare
$2,270,559
Medicare patients
1,460
Services billed
135,132
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 41% | |
| Diabetes | 33% | |
| Depression | 30% | |
| COPD | 27% | |
| Heart failure | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Influenza vaccine, trivalent derived from cell cultures 90661 | Office | 250 | 251 | $9,064 |
| Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 | Office | 21 | 21 | $2,449 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 56 | 286 | $218 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 54 | 175 | $167 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 37 | 98 | $53 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 19 | 28 | $10 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 16 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| FARXIGA |
|
$157 | 57 | — |
| MOUNJARO |
|
$131 | 140 | — |
| GEMTESA |
|
$129 | 19 | — |
| RYBELSUS |
|
$59 | 27 | — |
| Ozempic |
|
$37 | 238 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 16 in the dashboard with a free accountRecords
214 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.